MedPath

An Epidemiological Study of Acute Coronary Syndromes in The Greek Population. The TARGET Study

Completed
Conditions
Acute Coronary Syndromes
Registration Number
NCT01061086
Lead Sponsor
AstraZeneca
Brief Summary

This is a multicenter, 2-phase observational study of acute coronary syndromes (ACS) in Greece, designed to provide real world data on the risk factors of patients presenting to a hospital emergency department with an index event, as well as to depict the current management practices and outcomes of these clinical conditions in Greece.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
418
Inclusion Criteria
  • Diagnosis of an ACS (STEMI, NSTEMI, UA).
  • Informed Consent
Exclusion Criteria
  • Involvement in the planning and conduct of the study (applies to both AstraZeneca staff and staff at the study sites).
  • Participation in other clinical study in period between the index event and 6- month follow-up assessment with the exception of registering in registries or surveys not influencing the management of the ACS.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To evaluate the proportion of patients who are on target for LDL-C according to the 2004-updated NCEP ATPIII guidelines as calculated within the first 24-hours of hospital admission for an ACS.first visit - 1st day (cross-sectional part)
To estimate the proportion of patients enrolled in the cross-sectional part of the study that experiences a Major Adverse Cardiovascular Event (MACE) within a 6-month follow-up period.follow up visit - 6th month (prospective part)
Secondary Outcome Measures
NameTimeMethod
To estimate the proportion of patients admitted to the hospital with STEMI, NSTEMI and unstable angina.first visit - 1st day (cross-sectional part)
To estimate the "pain-to-door-time" throughout different regions in Greece.first visit - 1st day (cross-sectional part)
To estimate the time to first MACE and to estimate CV, non-CV and all cause mortality within the 6-month period following the index ACS event.follow up visit - 6th month (prospective part)

Trial Locations

Locations (1)

Research Site

🇬🇷

Chios, Greece

© Copyright 2025. All Rights Reserved by MedPath